Healthcare | January 05, 2023
Viatris acquires Oyster Point Pharma and Famy Life Sciences
Acquisitions have the potential to add at least $1 billion in sales by 2028
Acquisitions have the potential to add at least $1 billion in sales by 2028
The collaboration with IIT Kanpur will build on this foundation and expand the domain of research and development in healthcare technology
It ensures sufficient serum estradiol levels to alleviate menopausal symptoms
Over 30 years of deep life sciences industry experience with a wide range of expertise in corporate governance, capital markets, licensing and strategic collaborations
Kyfora Bio will focus on the synthesis of cationic polymers, lipids, and other materials used in nucleic acid delivery for cell and gene therapies.
This ambitious anti-TB campaign, as part of IOCL’s CSR, aims to ensure early identification of presumptive TB and prompt diagnosis using high-sensitivity diagnostic tests at the doorstep
For anaemia control in children (0-19 years) & resolves for Call to Action in this direction
Mock drills are being conducted across the country to review the preparedness for management of COVID-19
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
This FDC has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation
Subscribe To Our Newsletter & Stay Updated
